Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma
- Status
- TERMINATED
- Phase
- PHASE3
Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery
- Status
- RECRUITING
- Phase
- PHASE2
Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma
- Status
- COMPLETED
- Phase
- PHASE2
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
- Status
- COMPLETED
- Phase
- PHASE3
A Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab at the Fixed Dose 40 mg, Ifosfamide, Carboplatin, Etoposide (NICE-40) in Patients With Relapsed/Refractory Hodgkin Lymphoma
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Combination Immunotherapy in Rare Cancers Under InvesTigation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma
- Status
- TERMINATED
- Phase
- PHASE1
Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Using ctDNA to Determine Therapies for Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab
- Status
- WITHDRAWN
- Phase
- PHASE1
Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer
- Status
- COMPLETED
- Phase
- PHASE2
ARID1A and/or KDM6A Mutation and CXCL13 Expression
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2